StudyFinder

Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

RECRUITING

The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.

I'm interested

ALL
This study is NOT accepting healthy volunteers

Inclusion Criteria:

  • All patients undergoing allogeneic HSCT at our institution will be evaluated for graft rejection risk factors. Patients deemed high risk for graft rejection will have 2 or more of the following: mismatched or haploidentical donor, ex vivo t-cell depleted graft, prior history of graft rejection.

Exclusion Criteria:

  • Known hypersensitivity to any constituent of the study medication.

DRUG: Emapalumab 3 mg/kg, DRUG: Emapalumab 10 mg/kg

Hematopoietic Stem Cell Transplantation, Graft Failure

Jessica Anderson - jessica.anderson@cchmc.org
EARLY_PHASE1
NCT07244419
See this study on ClinicalTrials.gov

Back